AbCellera Biologics Inc. Earnings Per Share (Basic)
AbCellera Biologics Inc. (ABCL) reported Earnings Per Share (Basic) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- AbCellera Biologics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.18.
- AbCellera Biologics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.14.
- AbCellera Biologics Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.03.
- AbCellera Biologics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.19.
- AbCellera Biologics Inc. earnings per share, basic for fiscal 2025 was -$0.49.
- AbCellera Biologics Inc. earnings per share, basic for fiscal 2024 was -$0.55.
- AbCellera Biologics Inc. earnings per share, basic for fiscal 2023 was -$0.51, a 191.07% decline from fiscal 2022.
- AbCellera Biologics Inc. earnings per share, basic for fiscal 2022 was $0.56, a 0.00% change from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-05 | -$0.32 10-Q · filed 2026-08-05 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.14 10-Q · filed 2026-05-11 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.03 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.49 10-K · filed 2026-02-24 |
| 2025-09-30 | -$0.19 10-Q · filed 2025-11-06 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.46 10-Q · filed 2025-11-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.12 10-Q · filed 2026-08-05 | -$0.27 10-Q · filed 2026-08-05 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.15 10-Q · filed 2026-05-11 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-05-11 |
| 2024-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.55 10-K · filed 2026-02-24 |
| 2024-09-30 | -$0.17 10-Q · filed 2025-11-06 | -$0.30 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.44 10-Q · filed 2025-11-06 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-06-30 | -$0.13 10-Q · filed 2025-08-07 | -$0.26 10-Q · filed 2025-08-07 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-03-31 | -$0.14 10-Q · filed 2025-05-08 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2023-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-02-24 | -$0.51 10-K · filed 2026-02-24 |
| 2023-09-30 | -$0.10 10-Q · filed 2024-11-04 | -$0.20 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$0.34 10-Q · filed 2024-11-04 | -$0.45 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.11 10-Q · filed 2024-08-06 | -$0.24 10-Q · filed 2024-08-06 | -$0.35 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.26 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.14 10-Q · filed 2024-05-07 | -$0.24 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.15 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.18 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.01 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.04 derived: net income ÷ weighted average shares · filed 2025-02-27 | $0.56 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.09 10-Q · filed 2023-11-02 | $0.07 derived: net income ÷ weighted average shares · filed 2023-11-02 | $0.66 10-Q · filed 2023-11-02 | $0.87 derived: net income ÷ weighted average shares · filed 2024-02-20 |
| 2022-06-30 | -$0.02 10-Q · filed 2023-08-03 | $0.57 10-Q · filed 2023-08-03 | $0.78 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.71 derived: net income ÷ weighted average shares · filed 2024-02-20 |
| 2022-03-31 | $0.59 10-Q · filed 2023-05-04 | $0.81 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.74 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.73 derived: net income ÷ weighted average shares · filed 2024-02-20 |
| 2021-12-31 | $0.21 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.14 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.13 derived: net income ÷ weighted average shares · filed 2024-02-20 | $0.56 10-K · filed 2024-02-20 |
| 2021-09-30 | -$0.08 10-Q · filed 2022-11-08 | -$0.09 derived: net income ÷ weighted average shares · filed 2022-11-08 | $0.34 10-Q · filed 2022-11-08 | $0.71 derived: net income ÷ weighted average shares · filed 2023-02-21 |
| 2021-06-30 | -$0.01 10-Q · filed 2022-08-09 | $0.42 10-Q · filed 2022-08-09 | $0.83 derived: net income ÷ weighted average shares · filed 2023-02-21 | $0.90 derived: net income ÷ weighted average shares · filed 2023-02-21 |
| 2021-03-31 | $0.43 10-Q · filed 2022-05-10 | $0.89 derived: net income ÷ weighted average shares · filed 2023-02-21 | $0.99 derived: net income ÷ weighted average shares · filed 2023-02-21 | $1.07 derived: net income ÷ weighted average shares · filed 2023-02-21 |
| 2020-12-31 | $0.47 derived: net income ÷ weighted average shares · filed 2023-02-21 | $0.49 derived: net income ÷ weighted average shares · filed 2023-02-21 | $0.53 derived: net income ÷ weighted average shares · filed 2023-02-21 | $0.53 10-K · filed 2023-02-21 |
| 2020-09-30 | -$0.02 10-Q · filed 2021-11-10 | $0.01 derived: net income ÷ weighted average shares · filed 2021-11-10 | $0.01 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.03 10-Q · filed 2021-08-13 | $0.02 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$0.01 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$0.01 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |